EXEL – exelixis, inc. (US:NASDAQ)
Stock Stats
News
Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation [Yahoo! Finance]
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Royal Bank of Canada from $38.00 to $40.00. They now have an "outperform" rating on the stock.
Qiming-Backed AI Drug Discovery Startup Insilico Medicine Hits Unicorn Status With $110 Million Funding Round [Forbes]
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
Form 4 EXELIXIS, INC. For: Mar 03 Filed by: Haley Patrick J.
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
Form 4 EXELIXIS, INC. For: Feb 27 Filed by: Smith Julie
Form 4 EXELIXIS, INC. For: Feb 26 Filed by: MORRISSEY MICHAEL
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.